CLNN vs. ADCT, CHRS, GLSI, VXRT, DRUG, NKTX, PLX, ACTU, FATE, and PBYI
Should you be buying Clene stock or one of its competitors? The main competitors of Clene include ADC Therapeutics (ADCT), Coherus BioSciences (CHRS), Greenwich LifeSciences (GLSI), Vaxart (VXRT), Bright Minds Biosciences (DRUG), Nkarta (NKTX), Protalix BioTherapeutics (PLX), Actuate Therapeutics (ACTU), Fate Therapeutics (FATE), and Puma Biotechnology (PBYI). These companies are all part of the "pharmaceutical products" industry.
Clene vs.
ADC Therapeutics (NYSE:ADCT) and Clene (NASDAQ:CLNN) are both small-cap medical companies, but which is the better business? We will contrast the two businesses based on the strength of their risk, media sentiment, dividends, profitability, analyst recommendations, valuation, earnings, institutional ownership and community ranking.
ADC Therapeutics has a net margin of -300.00% compared to Clene's net margin of -8,556.77%. ADC Therapeutics' return on equity of 0.00% beat Clene's return on equity.
In the previous week, ADC Therapeutics had 1 more articles in the media than Clene. MarketBeat recorded 1 mentions for ADC Therapeutics and 0 mentions for Clene. ADC Therapeutics' average media sentiment score of 0.47 beat Clene's score of 0.00 indicating that ADC Therapeutics is being referred to more favorably in the media.
Clene has lower revenue, but higher earnings than ADC Therapeutics. Clene is trading at a lower price-to-earnings ratio than ADC Therapeutics, indicating that it is currently the more affordable of the two stocks.
ADC Therapeutics has a beta of 1.55, suggesting that its share price is 55% more volatile than the S&P 500. Comparatively, Clene has a beta of 0.25, suggesting that its share price is 75% less volatile than the S&P 500.
41.1% of ADC Therapeutics shares are owned by institutional investors. Comparatively, 23.3% of Clene shares are owned by institutional investors. 4.1% of ADC Therapeutics shares are owned by company insiders. Comparatively, 25.1% of Clene shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.
ADC Therapeutics currently has a consensus price target of $8.00, indicating a potential upside of 345.93%. Clene has a consensus price target of $55.25, indicating a potential upside of 1,041.53%. Given Clene's stronger consensus rating and higher possible upside, analysts plainly believe Clene is more favorable than ADC Therapeutics.
Clene received 14 more outperform votes than ADC Therapeutics when rated by MarketBeat users. Likewise, 79.12% of users gave Clene an outperform vote while only 67.44% of users gave ADC Therapeutics an outperform vote.
Summary
ADC Therapeutics beats Clene on 11 of the 19 factors compared between the two stocks.
Get Clene News Delivered to You Automatically
Sign up to receive the latest news and ratings for CLNN and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Related Companies and Tools
This page (NASDAQ:CLNN) was last updated on 1/21/2025 by MarketBeat.com Staff
Free CLNN Stock Alerts